JP2020519676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519676A5 JP2020519676A5 JP2019563255A JP2019563255A JP2020519676A5 JP 2020519676 A5 JP2020519676 A5 JP 2020519676A5 JP 2019563255 A JP2019563255 A JP 2019563255A JP 2019563255 A JP2019563255 A JP 2019563255A JP 2020519676 A5 JP2020519676 A5 JP 2020519676A5
- Authority
- JP
- Japan
- Prior art keywords
- acting
- long
- receptor agonist
- less
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000018 receptor agonist Substances 0.000 claims description 54
- 229940044601 receptor agonist Drugs 0.000 claims description 54
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 52
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 52
- 102000003812 Interleukin-15 Human genes 0.000 claims description 40
- 108090000172 Interleukin-15 Proteins 0.000 claims description 40
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 150000003839 salts Chemical group 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000000556 agonist Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023063333A JP7772733B2 (ja) | 2017-05-15 | 2023-04-10 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
| JP2025076268A JP2025111770A (ja) | 2017-05-15 | 2025-05-01 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506494P | 2017-05-15 | 2017-05-15 | |
| US62/506,494 | 2017-05-15 | ||
| US201762536966P | 2017-07-25 | 2017-07-25 | |
| US62/536,966 | 2017-07-25 | ||
| US201762582186P | 2017-11-06 | 2017-11-06 | |
| US62/582,186 | 2017-11-06 | ||
| US201862648240P | 2018-03-26 | 2018-03-26 | |
| US62/648,240 | 2018-03-26 | ||
| PCT/US2018/032817 WO2018213341A1 (en) | 2017-05-15 | 2018-05-15 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023063333A Division JP7772733B2 (ja) | 2017-05-15 | 2023-04-10 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519676A JP2020519676A (ja) | 2020-07-02 |
| JP2020519676A5 true JP2020519676A5 (enExample) | 2021-07-26 |
| JP7316222B2 JP7316222B2 (ja) | 2023-07-27 |
Family
ID=64274790
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563255A Active JP7316222B2 (ja) | 2017-05-15 | 2018-05-15 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
| JP2023063333A Active JP7772733B2 (ja) | 2017-05-15 | 2023-04-10 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
| JP2025076268A Pending JP2025111770A (ja) | 2017-05-15 | 2025-05-01 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023063333A Active JP7772733B2 (ja) | 2017-05-15 | 2023-04-10 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
| JP2025076268A Pending JP2025111770A (ja) | 2017-05-15 | 2025-05-01 | 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12036283B2 (enExample) |
| EP (1) | EP3624827A4 (enExample) |
| JP (3) | JP7316222B2 (enExample) |
| KR (2) | KR20250057110A (enExample) |
| CN (2) | CN111093688B (enExample) |
| AU (2) | AU2018270926C1 (enExample) |
| CA (1) | CA3060410A1 (enExample) |
| IL (2) | IL318018A (enExample) |
| MX (2) | MX2019013621A (enExample) |
| WO (1) | WO2018213341A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| KR20210020907A (ko) | 2018-05-14 | 2021-02-24 | 웨어울프 세라퓨틱스, 인크. | 활성화가능한 인터루킨 12 폴리펩타이드 및 이의 사용 방법 |
| CA3119049A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| US20230158164A1 (en) * | 2019-04-05 | 2023-05-25 | Nektar Therapeutics | Method for enhancing cellular immunotherapy |
| SG11202112541RA (en) | 2019-05-14 | 2021-12-30 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof |
| MX2021014189A (es) | 2019-05-20 | 2022-01-06 | Cytune Pharma | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. |
| AU2020384375A1 (en) | 2019-11-14 | 2022-05-26 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| KR20230096047A (ko) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| CA3195627A1 (en) | 2020-10-26 | 2022-05-05 | Stefano FERRARA | Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| EP4384204A1 (en) | 2021-08-13 | 2024-06-19 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| IL322075A (en) * | 2023-02-14 | 2025-09-01 | Akron Bioproducts Llc | Pharmaceutical compositions of interleukin for use in vivo |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| AU1096595A (en) | 1993-11-12 | 1995-05-29 | Gilead Sciences, Inc. | Thrombin mutants |
| DK0772624T3 (da) | 1994-04-06 | 2000-11-13 | Immunex Corp | Interleukin-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| JP4078032B2 (ja) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル，コーポレイション | 近位の反応性基を持つポリ（エチレングリコール）誘導体 |
| WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US20040136952A1 (en) | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| CN100343304C (zh) | 2002-12-31 | 2007-10-17 | 尼克塔治疗亚拉巴马公司 | 水解稳定的马来酰亚胺封端的聚合物 |
| CA2509939C (en) | 2003-01-06 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polymer derivatives |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| WO2006017853A2 (en) | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| CA2583274A1 (en) | 2004-10-05 | 2007-02-15 | Ochsner Clinic Foundation | Enhancement of b cell proliferation by il-15 |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| HUE025208T2 (en) | 2005-06-16 | 2016-03-29 | Nektar Therapeutics | Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates |
| CN106046370A (zh) | 2007-02-28 | 2016-10-26 | 塞瑞纳治疗公司 | 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物 |
| JP5588354B2 (ja) | 2008-02-01 | 2014-09-10 | アセンディス ファーマ エー／エス | 自己切断可能なリンカーを含むプロドラッグ |
| EP2350118B1 (en) * | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| CA2740904C (en) | 2008-10-21 | 2019-01-15 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| KR102269494B1 (ko) | 2010-07-30 | 2021-06-25 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
| JP2014506116A (ja) | 2010-11-12 | 2014-03-13 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Ｉｌ−２部分とポリマーとのコンジュゲート |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CA2963989A1 (en) * | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| CA3000211A1 (en) * | 2015-10-08 | 2017-04-13 | Nektar Therapeutics | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
-
2018
- 2018-05-15 JP JP2019563255A patent/JP7316222B2/ja active Active
- 2018-05-15 US US16/613,757 patent/US12036283B2/en active Active
- 2018-05-15 KR KR1020257012326A patent/KR20250057110A/ko active Pending
- 2018-05-15 AU AU2018270926A patent/AU2018270926C1/en active Active
- 2018-05-15 WO PCT/US2018/032817 patent/WO2018213341A1/en not_active Ceased
- 2018-05-15 IL IL318018A patent/IL318018A/en unknown
- 2018-05-15 CA CA3060410A patent/CA3060410A1/en active Pending
- 2018-05-15 CN CN201880032373.3A patent/CN111093688B/zh active Active
- 2018-05-15 CN CN202411943619.6A patent/CN119700941A/zh active Pending
- 2018-05-15 KR KR1020197036787A patent/KR102798243B1/ko active Active
- 2018-05-15 IL IL270634A patent/IL270634B2/en unknown
- 2018-05-15 EP EP18803095.1A patent/EP3624827A4/en active Pending
- 2018-05-15 MX MX2019013621A patent/MX2019013621A/es unknown
-
2019
- 2019-11-14 MX MX2024009988A patent/MX2024009988A/es unknown
-
2022
- 2022-05-31 AU AU2022203691A patent/AU2022203691B2/en active Active
-
2023
- 2023-04-10 JP JP2023063333A patent/JP7772733B2/ja active Active
-
2024
- 2024-06-06 US US18/735,818 patent/US20240424115A1/en active Pending
-
2025
- 2025-05-01 JP JP2025076268A patent/JP2025111770A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519676A5 (enExample) | ||
| US9018323B2 (en) | Polymer derivative of cytidine metabolic antagonist | |
| US8945527B2 (en) | Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates | |
| JP2019534308A5 (enExample) | ||
| JP2020063241A5 (enExample) | ||
| JP2020537501A5 (enExample) | ||
| JP2017526704A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2012532185A5 (enExample) | ||
| JP2016529321A5 (enExample) | ||
| JP2011530597A5 (enExample) | ||
| JP2006508091A5 (enExample) | ||
| Xu et al. | Immunologically effective poly (D-lactic acid) nanoparticle enhances anticancer immune response | |
| JP2013511540A5 (enExample) | ||
| CN1441676A (zh) | 用配体－免疫原缀合物治疗的方法 | |
| JP2010531879A5 (enExample) | ||
| CN111514306B (zh) | 一种增强抗肿瘤免疫治疗的富勒烯纳米颗粒 | |
| JP2008542399A5 (enExample) | ||
| KR20210142663A (ko) | 암을 치료하기 위하여 iRGD와 공동 투여되는 저용량 사이토카인 | |
| JP2020515688A5 (enExample) | ||
| US20240065987A1 (en) | Anti-cancer activity of adamantane derivatives | |
| JP2018530568A5 (enExample) | ||
| JP2010515762A (ja) | ポサコナゾール−ポリマー複合体、並びに、ポサコナゾールおよびそのポリマー複合体を使用した治療方法 | |
| US8383153B2 (en) | Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same |